Search hospitals

>

New York

>

New York

Columbia University

Claim this profile

New York, New York 10032

Global Leader in Alzheimer's Disease

Global Leader in Cancer

Conducts research for Breast Cancer

Conducts research for Amyotrophic Lateral Sclerosis

Conducts research for HIV Infection

629 reported clinical trials

85 medical researchers

Photo of Columbia University in New YorkPhoto of Columbia University in New York

Summary

Columbia University is a medical facility located in New York, New York. This center is recognized for care of Alzheimer's Disease, Cancer, Breast Cancer, Amyotrophic Lateral Sclerosis, HIV Infection and other specialties. Columbia University is involved with conducting 629 clinical trials across 954 conditions. There are 85 research doctors associated with this hospital, such as Richard Carvajal, MD, Ran Reshef, MD, Mark N. Stein, and Gary Schwartz, MD.

Area of expertise

1

Alzheimer's Disease

Global Leader

Columbia University has run 35 trials for Alzheimer's Disease. Some of their research focus areas include:

APOE4 positive
2

Cancer

Global Leader

Columbia University has run 26 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
FGFR3 positive

Top PIs

Clinical Trials running at Columbia University

Amyotrophic Lateral Sclerosis

Colorectal Cancer

Pancreatic Cancer

Multiple Myeloma

Diabetes

Lung Cancer

Cancer

Heart Failure

Frontotemporal Dementia

Stroke

Image of trial facility.

Genetic Counseling

for ALS

This program provides family members of individuals with familial ALS the opportunity to contribute to research focused on learning more about why motor neuron degeneration begins and how or why it progresses. This study provides genetic counseling and testing to help participants understand and manage their risk and determine if they want to learn their genetic status. This study will follow unaffected ALS gene mutation carriers on an annual basis to gather essential information that will ultimately help researchers develop novel therapies for the prevention and treatment of ALS.

Recruiting

1 award

N/A

9 criteria

Image of trial facility.

Biomarker Study

for ALS

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Recruiting

1 award

N/A

7 criteria

Image of trial facility.

Research

for Frontotemporal Dementia

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Recruiting

1 award

N/A

10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Columbia University?

Where is Columbia University located?

Who should I call to ask about financial aid or insurance network?

What insurance does Columbia University accept?

What awards or recognition has Columbia University received?